Abstract
Eight in vitro selection experiments under brincidofovir pressure elicited the known cytomegalovirus DNA polymerase amino acid substitutions N408K and V812L and the novel exonuclease domain substitutions D413Y, E303D, and E303G, which conferred ganciclovir and cidofovir resistance with 6- to 11-fold resistance to brincidofovir or 17-fold when E303G was combined with V812L. The new exonuclease domain I resistance mutations selected under brincidofovir pressure add to the single instance previously reported and show the expected patterns of cross-resistance.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.
MeSH terms
-
Antiviral Agents / pharmacology*
-
Cidofovir
-
Cytomegalovirus / drug effects*
-
Cytomegalovirus / genetics
-
Cytomegalovirus / growth & development
-
Cytomegalovirus / isolation & purification
-
Cytomegalovirus Infections / virology
-
Cytosine / analogs & derivatives*
-
Cytosine / pharmacology
-
DNA-Directed DNA Polymerase / genetics*
-
Drug Resistance, Viral / genetics
-
Foscarnet / pharmacology
-
Ganciclovir / pharmacology
-
Gene Expression
-
Humans
-
Microbial Sensitivity Tests
-
Mutation*
-
Organophosphonates / pharmacology*
-
Protein Domains
-
Viral Proteins / genetics*
Substances
-
Antiviral Agents
-
Organophosphonates
-
UL54 protein, Human herpesvirus 5
-
Viral Proteins
-
Foscarnet
-
brincidofovir
-
Cytosine
-
DNA-Directed DNA Polymerase
-
Cidofovir
-
Ganciclovir